Pages that link to "Q33224084"

The following pages link to Metformin as treatment for overweight and obese adults: a systematic review (Q33224084):

Displaying 28 items.

• Metformin and body weight (Q22250988) (← links)
• Metformin for obesity or overweight (Q24195145) (← links)
• Metformin for women who are obese during pregnancy for improving maternal and infant outcomes (Q24202468) (← links)
• Metformin for obesity or overweight (Q24236796) (← links)
• Metformin in obesity, cancer and aging: addressing controversies (Q28480735) (← links)
• Differential sympathetic outflow to adipose depots is required for visceral fat loss in response to calorie restriction (Q30252687) (← links)
• A systematic review on use of Chinese medicine and acupuncture for treatment of obesity (Q33686254) (← links)
• Carbohydrate modified diet & insulin sensitizers reduce body weight & modulate metabolic syndrome measures in EMPOWIR (enhance the metabolic profile of women with insulin resistance): a randomized trial of normoglycemic women with midlife weight gai (Q34258486) (← links)
• Metformin for atypical antipsychotic-induced weight gain and glucose metabolism dysregulation: review of the literature and clinical suggestions (Q34616707) (← links)
• Metformin beyond diabetes: pleiotropic benefits of metformin in attenuation of atherosclerosis (Q35114963) (← links)
• Bupropion for weight reduction (Q36691753) (← links)
• Outlook: metformin use in infertile patients with polycystic ovary syndrome: an evidence-based overview (Q37109632) (← links)
• Role of metformin for weight management in patients without type 2 diabetes (Q37162889) (← links)
• The impact of the metabolic phenotype on thyroid function in obesity. (Q37199254) (← links)
• FoxO1 controls lysosomal acid lipase in adipocytes: implication of lipophagy during nutrient restriction and metformin treatment (Q37577484) (← links)
• Effects of SLC22A1 Polymorphisms on Metformin-Induced Reductions in Adiposity and Metformin Pharmacokinetics in Obese Children With Insulin Resistance. (Q37583856) (← links)
• The effect of antiobesity drugs on waist circumference: a mixed treatment comparison (Q38130529) (← links)
• In this issue: Subtle clinical policy (Q42434585) (← links)
• Practical and Contextual Issues. (Q45815586) (← links)
• Pharmacotherapy of obesity (Q46865516) (← links)
• Metformin Use and Severe Dengue in Diabetic Adults. (Q49789764) (← links)
• Microbiota and metabolic diseases. (Q53688571) (← links)
• Metformin for women who are overweight or obese during pregnancy for improving maternal and infant outcomes (Q57174855) (← links)
• Evaluation of metformin in combination with rifampicin containing antituberculosis therapy in patients with new, smear-positive pulmonary tuberculosis (METRIF): study protocol for a randomised clinical trial (Q64074943) (← links)
• The Effect of Metformin in Experimentally Induced Animal Models of Epileptic Seizure (Q64250611) (← links)
• Anti-diabetic drugs. Weight reduction as a favourable side effect (Q83462595) (← links)
• Role of metformin in overweight and obese people without diabetes: a systematic review and network meta-analysis (Q90236672) (← links)
• The Effects of Combined Adiponectin-Metformin on Glucose and Lipids Levels in Mice and Acute Toxicity and Anti-Ulcerogenic Activity of Adiponectin Against Ethanol-Induced Gastric Mucosal Injuries in Rat (Q94189410) (← links)